The clinical trial has been completed… the results will be released soon!!!

During about 22 months, 12,358 prescreening interviews were completed in 17 European sites, resulting in 6710 visits. 1566 Candidates resulted eligible for the participation and 1519 were finally randomized.

On October 11th, during the 14th EUGMS congress (Berlin, Germany), there was a dedicated symposium on the SPRINTT project.

The chairman was prof. Roberto Bernabei, the Principal Investigator of the SPRINTT project.

In this occasion, prof Francesco Landi presented the baseline data from the clinical trial, whereas dr. Emanuele Marzetti described the Biomarker Ancillary Study: rationale, methods and expected outcomes. Finally dr. Daniel Rooks talked about anti-sarcopenic drugs in the pipeline.  

It is a pleasure to let you know that is now possible to read the full text of each of the 14 articles on the SPRINT-T project published in a special issue of Aging Clinical and Experimental Research in 2017.

A special issue of the journal Aging Clinical and Experimental Research entirely devoted to the SPRINTT project has been just published.

It includes 14 scientific papers presenting the SPRINTT project background and preliminary results.

Articles are published in the section for Researchers and for Healthcare providers.

What are the main aims of the SPRINTT trial?

The SPRINTT project is the largest European clinical study aimed at investigating whether physical disability may be prevented in older subjects with physical frailty and sarcopenia.

Two interventions will be compared in the SPRINTT trial:

1)       A multicomponent intervention, based on physical activity and nutrition counselling, with support of specific technological devices;